GLP-1 weight regain fears: what the data says about yoyo effects

What did @jennaaliseglp1 actually say?

Nothing about GLP-1 medications. The entire transcript is song lyrics: "What's it gonna be? Cause I can't pretend. And don't you wanna be. And friend." There are no medical claims, no dosing advice, no weight loss assertions, and no discussion of semaglutide, tirzepatide, or any related drug. The video is tagged with GLP-1 community hashtags, but the spoken content is music, not health information.

This matters because the hashtags alone, #glp1community, #noyoyoapp, #glp1tips, are what drew 86,000-plus viewers into this content. Whatever the creator intended, the verifiable transcript contains zero factual claims to assess. We can't fact-check a song.

Does the science back this up?

There is no claim here for science to support or contradict. The lyrics do not reference appetite suppression, insulin secretion, gastric emptying, or any mechanism associated with GLP-1 receptor agonists. We have nothing to evaluate.

That said, since viewers arrived via GLP-1 hashtags, it is worth noting what the actual evidence looks like in this space. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced roughly 15% mean weight loss versus placebo. These are the benchmarks any real GLP-1 claim would need to survive. This video does not make any such claim, so those benchmarks are simply context for the community watching.

What did they get wrong (or right)?

Nothing was wrong or right in a medical sense because nothing medical was said. The creator posted song content under GLP-1 hashtags, which is a common community engagement tactic on TikTok. It is not misinformation. It is also not information.

The potential concern here is structural, not factual. GLP-1 TikTok communities are heavily searched by people making real decisions about medications that carry real side effects, including nausea, pancreatitis risk, and thyroid C-cell concerns flagged in FDA labeling. When popular accounts in these spaces post non-informational content, they accumulate trust without accountability. That trust can later transfer to posts that do make claims. Researchers studying health misinformation on social media, including Chou et al. (2020, Journal of Medical Internet Research), have documented how parasocial relationships built through lifestyle content shape health decision-making downstream.

What should you actually know?

If you landed here because you are researching GLP-1 medications, here is what is actually established. Semaglutide and tirzepatide are FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. They work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying, which reduces appetite. They are not cures. They are chronic-use medications, meaning discontinuation is typically followed by weight regain, as shown in the STEP 4 withdrawal trial (Rubino et al., 2021, JAMA).

Compounded versions of semaglutide and tirzepatide exist in the market, but they are not equivalent to FDA-approved branded drugs in terms of verified potency, purity, or stability. The FDA has explicitly stated compounded drugs lack the same approval standards. Any platform or creator suggesting otherwise is misrepresenting the regulatory reality. This video makes no such claim, but the community it participates in sometimes does.

Talk to a licensed provider before starting, adjusting, or stopping any GLP-1 therapy. Social media, including this fact-check, is not a substitute for that conversation.